Trial · NCT07888595

Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks

NCT07888595, Early phase 1, Enrolling by invitation, Frontiers in Bioscience Research Institute and Aging

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks. Trials, record NCT07888595. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888595

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
NCT number: NCT07888595
Status: Enrolling by invitation
Phases: Early phase 1
Enrollment: 48 participants, estimated
Lead sponsor: Frontiers in Bioscience Research Institute and Aging
Conditions: Aging
Interventions: Topical anti-aging peptide serum
First posted: 2026-10-22
Last updated: 2026-10-22

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	START/REST biological age (transcriptomic tAge and proteomic pAge), in years	4 weeks	Change from baseline in biological age from the START/REST clocks - transcriptomic age (tAge) by qPCR and proteomic age (pAge) by plasma protein ELISA panel - in treated tissue (skin, hair, saliva, and/or peripheral blood) versus each participant's untreated reference sites and baseline. Reported in years.
Secondary	TART/REST transcriptional indices START^U/D (Psi) and REST (Omega), log10 ratio	4 weeks	Change from baseline in START\^U/D (Psi = log10\[START\_U/START\_D\]) and REST (Omega = log10\[REST/M.T.\]), measured by qPCR in treated tissue versus untreated reference sites and baseline. Unit: log10 ratio.
Secondary	Senescence-associated gene expression, 9-gene qPCR panel, relative expression	4 weeks	Change from baseline in mRNA expression of CDKN2A, CDKN1A, CDKN1B, CXCR2, LTA4H, TIMP1, MMP1, RELA, and RRM2 by qPCR, reported as relative expression (2\^-ddCt), in treated tissue versus untreated reference sites and baseline
Secondary	Plasma pro-inflammatory cytokines IL-6 and IL-8 by ELISA, pg/mL	4 weeks	Change from baseline in plasma interleukin-6 (IL-6) and interleukin-8 (IL-8), measured by ELISA and reported in pg/mL.
Secondary	Intracellular metabolites (alpha-ketoglutarate, ATP, NAD+), micromolar	4 weeks	Change from baseline in intracellular alpha-ketoglutarate, ATP, and NAD+, measured by enzymatic/colorimetric assay and reported in micromolar (uM), in treated tissue versus untreated reference sites and baseline.
Secondary	: NAD+/NADH ratio by enzymatic cycling assay	4 weeks	Change from baseline in the NAD+/NADH ratio, measured by enzymatic cycling assay and reported as a dimensionless ratio
Secondary	NF-kB activity (phosphorylated p65) by ELISA, OD at 450 nm	4 weeks	Change from baseline in NF-kB activity, quantified as cytoplasmic and nuclear phosphorylated p65 by Instant One ELISA (Thermo Scientific) and reported as optical density at 450 nm.
Secondary	Senescence-associated beta-galactosidase activity, nM 4-MU equivalents	4 weeks	Change from baseline in SA-beta-galactosidase activity, measured fluorometrically (excitation 360 nm, emission 465 nm) against a 4-methylumbelliferone (4-MU) standard and reported as nM 4-MU equivalents.
Secondary	Oxidative DNA damage (8-OHdG) by ELISA, ng/mL	4 weeks	Change from baseline in 8-hydroxy-2'-deoxyguanosine (8-OHdG), measured by ELISA and reported in ng/mL
Secondary	Reactive oxygen species and proteasome (UPS) activity, relative fluorescence units	4 weeks	Change from baseline in intracellular reactive oxygen species (DCFDA probe) and ubiquitin-proteasome (UPS) activity (fluorogenic substrate), each measured fluorometrically and reported in relative fluorescence units (RFU).

1 to 10 of 12Source ClinicalTrials.gov

See all 12 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
10839713	BACKGROUND	PubMed
12937682	BACKGROUND	PubMed
25738459	BACKGROUND	PubMed
28340339	BACKGROUND	PubMed
29986520	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07888595

GET https://conductscience.org/api/trials/v1/NCT07888595/registered

API reference For AI assistants